Contribute Try STAT+ Today

Introducing STAT’s Biotech Q4 Scorecard: Ten companies with important clinical trial and FDA milestones scheduled to read out over the next three months. We’ll use emojis to track the winners and losers as the outcomes are announced. Scroll down for a short explanation of each company and its pivotal readout.

 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Hello Adam,

    Are you considering the KITE/GILEAD axi-cel approval on/about November 29 FDA PDUFA date a forgone conclusion? It won’t exactly “break” Gilead with a CRL (Complete Response Letter) but if that happens, don’t you think it would result in a huge drop in the stock price?

Comments are closed.